Current status of innovative drug industry is briefly presented with emphasis on new biopharmaceuticals introduced in the years 1995-2007. Adverse effects and problems of safety and effectiveness of these pharmacotherapeutics are reviewed. A separate part of the manuscript is devoted to the newly introduced methods of molecular diagnostics based on pharmacogenomics and employed in personalized medicine. Theranostic approach consisting in a joint use of drugs and companion diagnostics are characterized.
Acetylsalicylic acid (ASA) and ?-2-pyrazylidene-?-cyano N-butyl acetamide (PD-101), a new antiaggregatory pyrazine derivative were tested for their genotoxicity in human lymphocytes in vitro using the sister chromatid exchange (SCE) technique. Both compounds were found to be inactive in inducing SCE in concentration from 1muM up to 1000 muM. The agents displayed inhibitory effect on cell kinetics.